BLFS

BioLife SolutionsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$36.00

+35.0% vs current

Most likely

Base case

45%

Probability

Target price

$32.40

+21.5% vs current

B-

Bear case

25%

Probability

Target price

$23.00

-13.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-11

AI commentary

Primary-source evidence supports a constructive but still monitoring-style view. The May 7, 2026 earnings release/8-K showed solid growth, profitability improvement, and reaffirmed guidance, but the main incremental debate is still operational margin repair rather than a fresh step-change catalyst [#SEC-8K-2026-05-07]. News flow is sparse, analyst-revision evidence in the packet is thin, and low coverage argues against high-conviction extrapolation.

RankAlpha Sentiment Codex - 2026-06-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06eventQ1 growth and 2026 outlook were reaffirmedHigh impact

Q1 2026 revenue rose to $27.5M, up 25% year over year, with GAAP net income of $1.2M and adjusted EBITDA of $6.2M, while management reiterated 2026 revenue guidance of $112.5M-$115.0M and said it expects full-year GAAP profitability [#SEC-8K-2026-05-07] [#SEC-8K-2026-02-26].

2026-12-31catalystBag-yield remediation remains the key margin swing factorMedium impact

Gross margin was 64% in Q1 2026 versus 67% a year earlier, and management linked the pressure to bag-format mix and manufacturing yields; if remediation and alternative configurations do not improve on schedule, margin recovery could slip and limit upside [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-08].

2027-03-31catalystCommercial therapy embed and trial exposure support recurring demandHigh impact

BioLife said its biopreservation media is embedded in 17 commercial CGTs, used in about 250 commercially sponsored U.S. CGT trials, and has visibility to 9 additional approvals, geographic expansions, earlier-line use, or new indications over the next 12 months, supporting a longer commercial demand runway [#SEC-8K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-11 • Updated nightlySource: Internal modelMethodology